التفاصيل البيبلوغرافية
| العنوان: |
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases |
| المؤلفون: |
Berger, Nathan A, Besson, Valerie C, Boulares, A Hamid, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert S, Curtin, Nicola J, Cuzzocrea, Salvatore, Dawson, Ted M, Dawson, Valina L, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew L, Snyder, Solomon H, Soriano, Francisco Garcia, Strosznajder, Robert P, Sümegi, Balázs, Swanson, Raymond A, Szabo, Csaba |
| المصدر: |
British Journal of Pharmacology, vol 175, iss 2 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2018 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Orphan Drug, Brain Disorders, Neurosciences, Rare Diseases, Lung, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Acute Disease, Animals, Chronic Disease, Drug Repositioning, Humans, Poly(ADP-ribose) Polymerase Inhibitors, Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy |
| جغرافية الموضوع: |
192 - 222 |
| الوصف: |
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.Linked articlesThis article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetocTest. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt0qj8g7s7; https://escholarship.org/uc/item/0qj8g7s7Test |
| الإتاحة: |
https://escholarship.org/uc/item/0qj8g7s7Test |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.EE6082EF |
| قاعدة البيانات: |
BASE |
